| 5.34 -0.04 (-0.74%) | 08-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.79 | 1-year : | 7.65 |
| Resists | First : | 5.81 | Second : | 6.55 |
| Pivot price | 5.37  |
|||
| Supports | First : | 4.63 | Second : | 3.85 |
| MAs | MA(5) : | 5.24  |
MA(20) : | 5.55 |
| MA(100) : | 6 |
MA(250) : | 6.32 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 45.7 |
D(3) : | 37.5 |
| RSI | RSI(14): 44.6 |
|||
| 52-week | High : | 13.5 | Low : | 3.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CLNN ] has closed above bottom band by 47.5%. Bollinger Bands are 13.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.56 - 5.59 | 5.59 - 5.61 |
| Low: | 5.25 - 5.27 | 5.27 - 5.3 |
| Close: | 5.29 - 5.34 | 5.34 - 5.38 |
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.
Thu, 06 Aug 2026
Clene Inc. (CLNN) insider relinquishes 799,358 warrant rights in fund shift - Stock Titan
Tue, 04 Aug 2026
Empery Asset Management (CLNN) discloses 7.17% beneficial stake in Clene - Stock Titan
Sun, 02 Aug 2026
Clene Inc. (CLNN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tue, 28 Jul 2026
CLNN Stock Falls After Roth Labels Accelerated Approval For ALS Drug A ‘Long Shot’ - Stocktwits
Sat, 25 Jul 2026
CLNN Options Chain — NASDAQ:CLNN - TradingView
Tue, 21 Jul 2026
When Will Clene Inc. (NASDAQ:CLNN) Breakeven? - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 1.05e+007 (%) |
| Held by Institutions | 17 (%) |
| Shares Short | 1,060 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.962e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -13 % |
| Return on Assets (ttm) | 740 % |
| Return on Equity (ttm) | -56.1 % |
| Qtrly Rev. Growth | 134000 % |
| Gross Profit (p.s.) | -88.59 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 120652 |
| Qtrly Earnings Growth | -3.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.08 |
| Dividend | 0 |
| Forward Dividend | 925390 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|